New Targets in Global Cardiovascular Risk Reduction: Considering the Whole Patient CME

Author Information and Disclosures

Release Date: June 27, 2008; Valid for credit through June 27, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The material presented here does not necessarily reflect the views of Medscape or companies that support educational programming on www.medscape.com. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

Copyright 2008 © American Society of Hypertension, Inc.
Pfizer
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Identify patients with elevated global risk and early-stage cardiovascular risk.
  2. Outline a plan for reducing global risk, and for preventing or slowing the progression of CVD, by intervening at numerous steps in the cardiovascular continuum.
  3. Describe the interrelationship between cardiovascular risk markers, from hypertension to dyslipidemia to vascular disease.
  4. Identify mechanistic approaches to optimize whole patient care by initiating multi-therapeutic regimens.
Authors and Disclosures

William J. Elliott, MD, PhD
Disclosure: William J. Elliott, MD, PhD, has disclosed that he has received grants-in-aid from the National Institutes of Health, and that he is a consultant for Novartis Pharmaceuticals Corp., Pfizer Inc., Bristol-Myers Squibb/Sanofi-Synthélabo Partnership, KV Pharmaceutical, AstraZeneca LP, Accu-Break Pharmaceuticals, Inc., King Pharmaceuticals. Dr. Elliott also has disclosed that he has served on the speakers' bureaus for Novartis Pharmaceuticals Corp., Pfizer Inc., Bristol-Myers Squibb/Sanofi-Synthélabo Partnership, Bristol-Myers Squibb Co., Sanofi-aventis, and that he receives royalties from Elsevier (Division of Harcourt).


David Good
Disclosure: David Good has disclosed no relevant financial relationships.
 
American Society of Hypertension
The American Society of Hypertension is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The American Society of Hypertension, Inc. (ASH) designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.